Are peptides legal? How the rules work in 2026

Three tiers, three different answers

• FDA-approved medicines: examples include insulin, GLP-1 drugs such as Wegovy and Zepbound, and bremelanotide (Vyleesi). These have been through FDA review and are prescribed for their approved uses or, at a clinician's judgment, off-label.
• Compounded medicines: made by a state-licensed pharmacy for an individual patient with a prescription. The FDA states compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality.
• Research chemicals: sold online with labels such as "for research purposes" or "not for human consumption." The FDA has warned consumers not to buy these for personal use.

How compounding pharmacies are allowed to use a peptide

Under section 503A of the federal drug law, a pharmacy compounding for individual patients can generally use a bulk ingredient only if it meets one of three tests: it has a qualifying USP or NF monograph, it's a component of an FDA-approved drug, or it appears on the FDA's 503A bulks list.

While the FDA evaluates ingredients nominated for that list, it uses interim categories. Category 1 substances are under evaluation and may be used under an interim policy. Category 2 substances raise significant safety concerns. Category 3 substances were nominated without enough information. The FDA says it doesn't plan to place substances nominated on or after January 7, 2025, into these categories.

Where popular peptides stand as of October 2026

• BPC-157, TB-500, KPV, MOTS-c and epitalon: not FDA-approved. Previously in Category 2; in April 2026 their nominations were withdrawn and the FDA moved them to its nominated-but-withdrawn list. In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend them for the 503A bulks list for specific proposed uses, against FDA staff advice. The FDA has not completed the rulemaking that would add them.
• DSIP (emideltide): also withdrawn from Category 2 in April 2026. In July 2026 the advisory committee voted against recommending it.
• GHK-Cu: listed in Category 1 for non-injectable routes only, after the injectable nomination was withdrawn.
• Sermorelin: a component of a previously FDA-approved drug, Geref. The FDA determined in 2013 that Geref was not withdrawn for safety or effectiveness reasons. Sermorelin today is available only through compounding.
• Bremelanotide (PT-141): FDA-approved as Vyleesi for a specific group of premenopausal women; compounded PT-141 is not FDA-approved.
• Semaglutide and tirzepatide: FDA-approved in branded form; compounded versions are not FDA-approved.

What an advisory committee vote does and doesn't mean

The Pharmacy Compounding Advisory Committee advises the FDA; it doesn't make the final decision. If the FDA agrees, it publishes a proposed rule, takes public comments and then issues a final rule. There is no fixed deadline for those steps.

Until that process finishes, a favorable vote doesn't by itself put a peptide on the 503A list, and adding a substance to that list would still not make it FDA-approved. Legal commentators have cautioned pharmacies against treating the votes as authorization. Because the situation is moving, details on this page may change.

State law and sport add more layers

State boards of pharmacy have primary day-to-day oversight of compounding pharmacies, and states can set their own rules. A product that one pharmacy can dispense in one state may not be available in another.

If you compete in tested sport, legality isn't the only question. USADA notes that BPC-157 is prohibited under the WADA list, and many other peptides are too.

Staying on the right side of the rules

• Get peptides only with a prescription from a licensed clinician who has reviewed your health.
• Use a state-licensed U.S. pharmacy and ask which pharmacy is filling your prescription.
• Ask about the specific peptide's current FDA status, not peptides in general.
• Avoid any product labeled for research or not for human consumption.
• Be wary of steep discounts, no-prescription offers and vague answers about sourcing.

Why approval and compounding eligibility are different

It's easy to blur two separate questions. FDA approval means a specific product was tested in clinical trials and reviewed for safety, effectiveness and manufacturing quality for a defined use. Compounding eligibility only means a pharmacy may use an ingredient to prepare a medicine for an individual patient.

So even if a peptide is eventually added to the 503A bulks list, it won't become FDA-approved, and its effects in people won't be any better established than they are today. Keep that distinction in mind when you read headlines about peptides being "cleared" or "legalized."

How HealifyMD handles regulatory status

HealifyMD clinicians explain each peptide's status before prescribing. Prescriptions are filled by licensed U.S. pharmacies, and HealifyMD only arranges a prescription when a licensed pharmacy confirms it can lawfully dispense the product under current federal and state rules. If the rules change, availability may change too.